Abstract
Despite decades of research, complications associated with dysfunctional labor are leading causes of maternal and neonatal morbidity. Currently available experimental models are not sufficient to understand the complex mechanisms underlying human labor nor to test new therapeutic approaches. We sought to develop a bioprinted tissue model of pregnant human myometrium that replicates the morphological, contractile and molecular characteristics of native pregnant human uterine myometrium as a resource to accelerate basic discovery and pharmacological testing. We have utilized primary human uterine smooth muscle cells to bioprint myometrial tissue rings containing >75% viable cells with elongated, smooth muscle morphology. Immunofluorescence confirmed expression of smooth muscle markers (caldesmon, alpha smooth muscle actin, and smooth muscle myosin), contractile-associated proteins (oxytocin receptor, prostaglandin receptors and connexin-43), and steroid hormone receptors (estrogen and progesterone receptors) characteristic of pregnant human uterine myometrium. Bioprinted tissues contracted in response to physiological agonists oxytocin (p < 0.001), prostaglandin F2α (p = 0.003), and prostaglandin E2 (p < 0.001), and relaxed in response to the nitric oxide donor S-nitrosoglutathione (p = 0.004). Further development of this model could provide an abundant and homogeneous tissue source to facilitate mechanistic studies and test agents to modulate labor.
Introduction
Human labor is characterized by the development and maintenance of coordinated contractions of the uterine smooth muscle (myometrium). The premature initiation of this process results in preterm delivery, a leading cause of neonatal morbidity and mortality (; ). Weak or irregular contractions lead to labor dystocia and the need for delivery by Caesarean section, while excessive contraction strength or frequency can result in hypoxia and fetal distress (; ). Despite decades of research, the molecular pathways underlying labor are not completely understood and complications associated with labor dystocia and preterm delivery remain leading causes of Caesarean section and neonatal morbidity respectively (). Therefore, there is an urgent need to develop biologically relevant model systems of normal and pathological pregnancy conditions.
Several animal models have been used to study the molecular mechanisms underlying the transition of the uterus to the contractile state (; ). Rodent models are relatively inexpensive and can be genetically manipulated; however, differences between the regulation of rodent and human parturition include gestation length, fetal numbers, placentation, progesterone regulation, and uterine anatomy, histology, and physiology (; ; ; ). Large animal models (ovine and porcine) are expensive and exhibit differences in gestation length, fetal numbers, placentation, uterine anatomy and hormonal regulation (; ; Sun et al., 2023). Non-human primates serve as excellent physiological models, but their accessibility is limited by cost (; ; ). No animals display a high prevalence of spontaneous preterm birth, and available models require interventions to induce early labor (). Therefore, it is important to confirm findings from animal models in relevant human models (; ).
Another model system that has been instrumental to elucidating mechanisms underlying uterine smooth muscle function is the 2D cell culture model (; ; ). Cultured uterine myocytes have the advantages of convenience, high reproducibility, and high throughput. Uterine myometrial cells grown in culture maintain expression of key contractile proteins (; ). Cells in 2D culture cannot be used for contractile studies, with the exception of myometrial cells grown on collagen gel lattices (). Another disadvantage of 2D models is that monolayers may not accurately reflect the complex cellular interactions found in three-dimensional tissues, resulting in altered gene transcription, protein production, cytoskeletal structure, and cellular function (; Souza et al., 2017; ). Perhaps the most physiologically relevant contractile studies have been performed with ex vivo human uterine myometrial tissue strips (; ; ). Human myometrial tissues are obtained from patients undergoing elective Cesarean-section and myograph-based experiments allow measurement of variables such as contraction interval, amplitude, and force. Organ tissue bath experiments allow the assessment of responses to pharmacological agents administered directly to tissues in real time; however, limitations include a limited window of tissue viability and high level of heterogeneity (; ).
There is a need to create functionally relevant human uterine tissue models to accelerate basic pregnancy research and to reduce the need for animal testing (; Wheeler and Leach, 2025). Three-dimensional (3D) engineered tissue models have emerged as powerful complimentary tools to study contraction dynamics. Bioengineered models of normal and pathological tissues have been developed, including contractile models of skeletal, airway, vascular, and cardiac muscle (; ; ; ; ; ; ; ; Song et al., 2023; ; Tung et al., 2024; ). We sought to develop a comparable bioprinted uterine myometrial tissue model that aims to replicate native pregnant human uterine myometrium.
Materials and methods
Tissue procurement and uterine smooth muscle cell isolation
Uterine tissue biopsies were obtained from the upper edge of the transverse incision in the lower uterine segment from women delivering via Caesarean section at Renown Regional Medical Center, Reno, NV under informed consent and with approval from the University of Nevada and Renown Regional Medical Center Institutional Review Boards (Ulrich et al., 2019; Ulrich et al., 2025). Tissue donors were pregnant individuals at 38–39 weeks of gestation in the absence of HIV or hepatitis infection. Medical history data was collected and de-identified. Patient ages ranged from 24 to 35 years (mean age 28 years). All were Caucasian, singleton pregnancies, and parity 1–5 (mean 2).
Uterine myometrium was dissected and used for myometrial cell isolation. Myometrial cells were separated using a gentleMACS dissociation instrument (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were strained, centrifuged, and resuspended in Dulbecco’s modified Eagle medium (DMEM; ThermoFisher Scientific) containing 10% fetal bovine serum and antibiotics. Growth media was supplemented with 60 nM 17β-estradiol and 600 nM progesterone to mimic third trimester plasma concentrations. Isolated cells were allowed to proliferate in a humidified incubator at 37 °C, 5% CO2.
Rheology
A rheometer (MCR 92, Anton Paar, Ashland, VA) equipped with a cone-plate measuring system (cone angle of 1°, cone diameter of 50.0 mm, and cone-to-plate gap of 0.102 mm) was employed to evaluate the rheological properties of the prepared alginate-Matrigel composites. The steady shear rate sweeps were carried out to measure the yield stress and viscosity of the composites pre- and post-crosslinking. Specifically, the composites with 0.5, 0.6, and 0.7% (w/v) alginate were selected as the pre-crosslinking samples, while the composites with 0.5% and 0.6% (w/v) alginate were used as the post-crosslinking samples. In the measurements, the shear rate was increased from 10–2 to 10–3 s-1 and the shear stress and viscosity at each shear rate were recorded. For the yield stress, the obtained shear stress-shear rate plots were fit into the Herschel-Bulkley model (Zhu et al., 2005). All measurements were conducted at room temperature.
Bioink preparation
An overview of the experimental design is shown in Figure 1. After 3-9 passages, primary human myometrial cells were trypsinized, collected by centrifugation, and combined with bioink for 3D printing. For initial optimization experiments, bioink contained 2.5 × 107 myometrial cells/mL in 50% Matrigel (Corning) and 0.5%, 0.55%, 0.60%, 0.70%, or 0.75% (w/v) NOVATACH VLVG 4GRGDSP alginate (Novamatrix) in Dulbecco’s Phosphate-Buffered Saline (DPBS) lacking calcium and magnesium (ThermoFisher Scientific).
FIGURE 1
3D bioprinting parameters
Bioink was deposited onto Transwell culture inserts (Grenier Biosciences) in 14-layer, 14 mm Mean Diameter rings using an RX1 Microfluidic Bioprinter (Aspect Biosystems Ltd., Vancouver, Canada) (). The microfluidic device allows crosslinking directly in the printhead by combining bioink with a CaCl2-based crosslinker (Aspect Biosystems). The crosslinker coaxially surrounds the alginate bioink to rapidly form an insoluble hydrogel fiber (). Print conditions were 69 mbar pressure cell/bioink solution, 55 mbar pressure buffer (Aspect Biosystems Ltd.), 55 mbar pressure crosslinker (125 mM CaCl2 in 2% polyvinyl alcohol, Aspect Biosystems Ltd.), print speed 25 mm/s. For all subsequent experiments bioink containing 50% Matrigel and 0.6% RGD-alginate was used. Approximately 12 tissue rings were produced per mL bioink with each tissue ring containing approximately 2 million cells.
Cell proliferation and differentiation
Myometrial cells were allowed to proliferate in hydrogel rings for 24 h and then the tissue rings were transferred to DMEM supplemented with 1% insulin, transferrin, and selenium (ITS, Gibco), proline [40 mg/L L-proline, 10 mg/L trans-4-hydroxy-L-proline, and 0.1 mg/L L-ascorbic acid 2-phosphate, Millipore Sigma (Thorrez et al., 2018)], 1% penicillin/streptomycin (ThermoFisher Scientific), 60 nM 17β-estradiol, and 600 nM progesterone (Sigma-Aldrich). An 8-mm diameter Pyrex cloning cylinder was placed in the center of each bioprinted ring to prevent excess spontaneous tissue area reduction. Media was changed every 2–3 days and cells within synthetic rings were allowed to differentiate and form interconnected networks at 37 °C, 5% CO2. After 1 week, synthetic tissue constructs were treated with 0.4 mg/mL alginate lyase in differentiation medium for 5 min at 37 °C and then placed at 4 °C for 15 min to dissolve remaining alginate (). Tissue rings were allowed to differentiate an additional 6–7 days at 37 °C, 5% CO2.
Analysis of cell viability and morphology
Cell viability and morphology assessments were performed on unfixed, intact tissue rings (live cells) 2 weeks post-printing. Tissue rings were submerged in PBS containing calcium and magnesium. Synthetic rings were incubated with 2 µM Calcein AM and 1 μg/mL Hoechst for 20 min at 37 °C. Propidium iodide was added to 1 μg/mL for an additional 5 min at 37 °C. Tissue rings were rinsed with PBS, and fluorescent images were captured on an Olympus Fluoview 1,000 confocal microscope (Olympus). In some experiments, z-stack images were captured to subjectively assess cells in 3 dimensions (Supplementary Video S1).
Cell morphology and cell viability images were analyzed using ImageJ/FIJI software. The percentage of viable cells was determined by dividing the number of cells stained with Calcein AM (living cells) by the number of cell nuclei detected with Hoechst (total cells). Cell elongation percentage was determined by comparing total number of visibly elongated cells divided by cells that were visibly circular. Native human uterine smooth muscle is characterized by high numbers of parallel elongated cells, and this morphology is expected to promote contraction.
Immunofluorescence
Two weeks after printing, synthetic tissue constructs were submerged in 4% paraformaldehyde for 5–10 min, permeabilized in 0.5% Triton X-100 for 3 min, washed 3 × 5 min in PBS, and blocked in PBS containing 5% BSA at 4 °C overnight. Tissues were incubated with primary antibody diluted in PBS containing 1% BSA in a humid chamber at 4 °C overnight, followed by secondary antibody diluted in PBS containing 1% BSA at 4 °C overnight. A complete list of antibodies can be found in Supplementary Table S1. Tissues were incubated in 1 μg/mL Hoechst for 5 min at room temperature, followed by 3 washes with PBS. Fluorescent images were captured from intact tissue rings with an Olympus Fluoview 1,000 confocal microscope (Olympus).
Contraction and relaxation experiments
Experiments were performed to determine if synthetic myometrial constructs would respond to physiological contractile and relaxing agents. At 14 days post printing, Pyrex cylinders were removed using tweezers and a pipette tip to gently push the tissue ring constructs off the cylinders. Rings were then allowed to equilibrate 1–2 h at 37 °C, 5% CO2. Tissue constructs were treated with either 10 nM oxytocin (OT), 1 µM prostaglandin F2α (PGF2α), 1 µM prostaglandin E2 (PGE2), or 100 µM S-nitrosoglutathione (GSNO) and incubated at 37 °C, 5% CO2 for 2 h. Control was equal volume of PBS for all groups. Myometrial tissue constructs were photographed prior to addition of contractile (OT, PGF2α, and PGE2) and relaxing (GSNO) agents and 2 h post treatment. Changes in inner ring diameter were auto calculated in ImageJ FIJI and the percent change in area was calculated in Excel. All contractile and relaxation experiments were performed 2–3 times with 3-6 technical replicates per treatment.
Statistical analyses
Treatments were coded and samples randomized so those collecting and analyzing data were blinded to the treatment group (). Experiments were performed with 3-6 technical replicates per group. Differences between groups were determined using unpaired, two-tailed t-tests or One-way ANOVA with Tukey’s multiple comparisons test.
Results
Rheological measurements
To investigate the effects of alginate concentration on the printability of alginate-Matrigel composites, the yield stress (τ0) () and dynamic viscosity () were selected as the primary rheological parameters. The measurements are illustrated in Figure 2. For the pre-crosslinking composites, all the samples exhibited a weak yield-stress property. With the increase of alginate concentration from 0.5% to 0.6% and 0.7% (w/v), the yield stress increased slightly from 0.004 to 0.008 and 0.010 Pa (Figure 2). The weak yield stress is attributed to the self-assembled protein network of Matrigel, which comprises a complex mixture of proteins, primarily laminin, collagen IV, entactin, and other extracellular matrix components (; ), enabling the composite to behave solid-like at lower shear stresses. As shown in Figure 2, the viscosity continuously decreased with the increasing shear rate, demonstrating a typical shear-thinning behavior of the composites that facilitates the ink extrusion during bioprinting (; ). After crosslinking by CaCl2, the yield stress of the alginate-Matrigel composites was significantly enhanced. As illustrated in Figure 2, the composites with 0.5% and 0.6% (w/v) alginate have the yield stresses of 17.19 and 68.23 Pa, respectively, upon crosslinking, which can be explained by the formation of a densified 3D networked microstructure from alginate chains. Simultaneously, the crosslinked composites still possessed the shear-thinning behavior, as shown in Figure 2, indicating that these composites are still extrudable if a higher shear stress is applied.
FIGURE 2
Optimization of cell viability and morphology
We determined the bioink conditions for optimal human uterine smooth muscle cell viability and morphology. Our early observations suggested bioink containing 50% Matrigel produced tissues with higher cell viability and elongation compared to bioink containing lower Matrigel concentrations or single ECM components (e.g., collagen or fibronectin alone, data not shown), consistent with the observation that high Matrigel concentrations promoted elongated morphology in bioprinted skeletal muscle (). RGD alginate was selected for its beneficial effects on cell adhesion and differentiation (; ). Cell viability was 65.2% when bioink was prepared with 0.5% alginate and increased to 76.2% with 0.6% alginate (p = 0.0082) and 79.8% with 0.7% alginate (p = 0.0012). The percentage of elongated cells increased from 63.5% when bioink contained 0.5% alginate to 84.3% with 0.6% alginate. We determined that bioink containing 50% Matrigel and 0.6% RGD-alginate provided the highest levels of elongated cells while retaining high numbers of viable cells (Figure 3).
FIGURE 3
Expression of appropriate tissue markers
Immunofluorescence experiments were performed to confirm the expression of smooth muscle, uterine, and contractile associated proteins in bioprinted myometrial tissue constructs. We observed appropriate expression and localization of smooth muscle markers (caldesmon, α smooth muscle actin, and smooth muscle myosin), contractile-associated proteins (oxytocin receptor, prostaglandin receptors and connexin-43), and steroid hormone receptors (estrogen and progesterone receptors) in synthetic tissue constructs (Figure 4) (; ; ; ; ; ; ).
FIGURE 4
Synthetic human myometrial tissues respond to contractile agonists
We detected oxytocin receptor expression in the bioprinted myometrial tissue constructs (Figure 4) and observed a 34% reduction in tissue ring area in response to 10 nM oxytocin (compared to 25% in response to vehicle; p = 0.001, Figure 5). These observations support the hypothesis that myocytes within the synthetic tissues can produce a physiological response to the contractile agonist oxytocin (Wray and Arrowsmith, 2021).
FIGURE 5
The bioprinted myometrial tissues expressed COX-2 and prostaglandin receptors (data not shown) and contracted in response to both PGE2 and PGF2α (Figure 5). Tissue ring area was reduced 52.7% in response to PGF2α, compared to 21.5% for the vehicle controls (p = 0.002). Similarly, treatment with PGE2 reduced bioprinted tissue ring area 21.9% compared to 8.7% in vehicle-treated controls (p = 0.001). These data are consistent with observations that these inflammatory mediators promote myometrial contractions during labor (). Together these results indicate the bioprinted myometrial tissue constructs displayed a contractile response to prostaglandins as expected for human uterine smooth muscle.
Synthetic human myometrial tissues relax in the presence of nitric oxide donor
Previous studies have demonstrated that uterine smooth muscle exhibits a relaxation response distinct from other smooth muscle tissues. Nitric oxide (NO) induces relaxation of uterine smooth muscle in a dose-dependent manner, independent of cyclic guanosine monophosphate (cGMP) pathways (). Bioprinted tissue ring area increased 4.8% 2 h after addition of the NO donor S-nitrosoglutathione, which was significantly different from the 2.5% reduction in area observed in vehicle-treated control tissues. Our synthetic myometrial model demonstrated relaxation in response to the nitric oxide donor (Figure 5), providing evidence that our model can respond effectively to pharmacological intervention.
Discussion
In recent years, bioprinted models of several reproductive tissues have been developed, including ovary, placenta, uterine endometrium, and the maternal-fetal interface (). The first in vitro 3D model of uterine myometrium consisted of primary human uterine smooth muscle cells carrying magnetic nanoparticles that were assembled into 3D ring structures via magnetic force (Souza et al., 2017). Immediately after magnet removal, the tissue rings displayed spontaneous contractile activity, which was inhibited with two commonly used tocolytics. To date, this model has not been used to assess agonist-induced contractions; however, this study confirmed pregnant human myometrial cells retain the ability to respond to tocolytic agents in culture. More recent data have shown that oxytocin induces intracellular calcium transients in human myometrial tissues printed in polyacrylamide hydrogels (). Here, we report the development of the first bioprinted tissue model of pregnant human myometrium that responds to multiple physiological contractile stimulants as well as a known tissue relaxant. This model does not require cells uptake magnetic particles, which may alter multiple cellular functions (). Another relative advantage of the microfluidic bioprinting platform is that multiple cell types can be deposited in layers, so this model can serve as a foundation to develop models in which interactions between the myometrium and other cell types (such as immune or epithelial cells) can be studied. The 3D culture conditions we describe are also compatible with scalable technology to measure contraction force and frequency ().
The bioprinted ring structure was chosen because it was expected to allow diffusion of gases and molecules through the tissue while supporting 3D intercellular interactions and allowing basic contraction assays to be performed (). The major uterine contractile agonists of pregnancy are oxytocin and prostaglandins. Oxytocin was the first uterine contractile agonist discovered, and synthetic analogs are commonly used to induce or accelerate labor (Vigneaud et al., 2002; Uvnas-Moberg, 2024). During labor, oxytocin released from the pituitary binds to myometrial oxytocin receptors to initiate a series of protein phosphorylation events resulting in activation of the contractile machinery (Wray and Arrowsmith, 2021). In addition, locally produced oxytocin promotes prostaglandin production (Uvnas-Moberg, 2024). PGE2 is FDA approved for labor induction () and PGF2α also promotes uterine contraction (). Bioprinted tissues were comprised of myometrial cells obtained from term pregnant human myometrium and maintained under high levels of estradiol and progesterone to mimic physiological third trimester concentrations. The bioprinted myometrial tissue model displayed measurable contractile responses to three known agonists (oxytocin, PGE2, and PGF2α) at concentrations previously used in ex vivo pregnant human myometrial tissues by our laboratory and others (; ; Ulrich et al., 2019). The observed PGE2 contraction response supports the hypothesis that our model specifically replicates term pregnant human myometrium, in contrast to nonpregnant human myometrium which relaxes in response to PGE2 ().
The observed contraction and relaxation responses suggest the myometrial tissue model we describe can serve as a foundation for the development of complex human uterine tissue models, including those for pathological pregnancy conditions such as preterm labor and induction failure. Currently available medications to reduce preterm labor are only effective for 48 h, which is largely insufficient to prevent preterm delivery () Recent data indicate macrophages promote development of the contractile phenotype and mediate preterm parturition (; ). Addition of immune or other cell types may allow the creation of bioengineered tissues that functionally represent human preterm laboring myometrium. The microfluidic bioprinting platform allows the deposition of multiple cell types in layers, so this bioprinted model can serve as a foundation to develop models in which interactions between the myometrium and other cell types can be studied. Labor dystocia is treated with the administration of synthetic oxytocin, but patient responses are highly variable, and oxytocin supplementation does not reduce cesarean delivery rates (). Proposed uterine factors underlying dystocia include inadequate expression of pro-labor proteins, insufficient contractile force, and metabolic fatigue (). Bioprinted uterine tissues could be adapted to represent preterm labor and labor dystocia to explore underlying mechanisms and to identify and test new tocolytics and uterotonics. The idea that myometrial tissue models of pathological pregnancy conditions can be developed is supported by recent reports of engineered tissue models that replicate cardiac, skeletal muscle, and gastrointestinal disease phenotypes (Workman et al., 2017; ; Tsui et al., 2022; ; ; Wheeler and Leach, 2025).
One limitation of this model is the need for characterization of transcript and protein expression. Previous work has shown that, after four passages in culture, uterine smooth muscle cells display altered transcript levels for key labor-associated genes compared to parent tissues, including elevated ESR1 and GJA1 transcript levels and reduced OXTR and PGR transcript levels, and the reduction in progesterone receptor expression was confirmed at the protein level (; ). In these experiments, the smooth muscle cells were maintained in serum to stimulate proliferation, followed by incubation in low serum conditions overnight. While we do not report quantitative expression assays, future experiments will determine if bioprinted myometrial tissues display elevated expression of markers compared to cells in 2D culture, as reported for other 3D tissue models (; ). Myometrial cells within the bioprinted tissues required culture in serum-free differentiation medium for 2 weeks to attain optimal morphology (data not shown). Other reports suggest the longer differentiation times are required for 3D tissues to develop optimal morphology and function, and this may be associated with changes in gene expression (; ). Additionally, the bioprinted myometrial tissues likely contain low levels of other cell types in addition to myometrial smooth muscle cells that may contribute to expression differences and tissue function ().
These bioprinted tissue constructs could provide a foundation for a variety of mechanistic studies, including “knock out” or overexpression experiments to elucidate or confirm important players in contraction and relaxation pathways. Immortalized human uterine smooth muscle cells have successfully been used for genetic manipulation experiments, including CRISPR editing to modify the endogenous oxytocin receptor gene (). However, to our knowledge, these experiments have not been replicated in a three-dimensional tissue environment which our current model can provide. It is important to note that bioprinted myometrial tissues exhibit reduced mechanical properties compared to their native counterparts, primarily due to weak interfacial strength between printed layers, uniform filament orientation different from native muscle fiber alignment, and porous microstructure of the bioink upon crosslinking. Since the bioprinted tissues are not strong enough to withstand the tension necessary for myography experiments, measurements of contraction force, frequency, or duration cannot currently be obtained. Addition of biomaterials such as fibrin and elastin could improve tensile strength and elasticity of bioprinted myometrium (; Wang et al., 2024). Incorporation of nanofibers produced via electrospinning improved cell morphology and tensile strength in a scaffold-based uterine tissue model (). Despite these limitations, this model can serve as a foundation for future research aimed at developing sensitive, scalable contraction and relaxation assays in bioprinted myometrium (; ; ).
In conclusion, we have developed a uterine myometrial tissue model that phenotypically and functionally represents morphological, contractile, and molecular characteristics of term pregnant human myometrium. This work represents a foundational step toward the long-term goal of developing bioprinted uterine tissue models that represent multiple pathological etiologies of pregnancy and can serve as an accessible resource for basic scientific discovery, toxicology studies, drug screening, and preclinical testing.
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://datadryad.org/stash, doi: 10.5061/dryad.gf1vhhn0m.
Ethics statement
The studies involving humans were approved by University of Nevada, Reno IRB 1397596-1. The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired as part of our previous study for which ethical approval was obtained. Written informed consent for participation was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and institutional requirements.
Author contributions
CU: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing. KS: Investigation, Writing – review and editing. LB: Formal Analysis, Investigation, Writing – review and editing. WH: Formal Analysis, Investigation, Methodology, Writing – review and editing. JK: Investigation, Writing – review and editing. JO: Investigation, Writing – review and editing. LP: Writing – original draft, Writing – review and editing. JP: Data curation, Formal Analysis, Writing – review and editing. DQ: Formal Analysis, Writing – review and editing. GS: Investigation, Writing – review and editing. AS: Investigation, Validation, Writing – review and editing. JW-F: Investigation, Validation, Writing – review and editing. RW: Investigation, Writing – review and editing. AW: Methodology, Writing – review and editing. YJ: Formal Analysis, Methodology, Supervision, Writing – original draft, Writing – review and editing. HB: Conceptualization, Formal Analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Visualization, Writing – original draft, Writing – review and editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by grants from the National Institute of General Medical Sciences (P20 GM103440, NV INBRE), (P20 GM130459, NV COBRE HSTRI Core), (T34 GM145539, MARC Nevada, JO), (U54 GM104944, MW CTR-IN), and the Eunice Kennedy Shriver National Institute for Child Health and Human Development (R01HD100624, HB) at the National Institutes of Health.
Acknowledgments
This work is solely the responsibility of the authors and does not necessarily represent the official views of NIH. We thank the University of Nevada McNair Scholars Program (JO, AS) and Office for Undergraduate Research (AB, JO, GS, AS, JWF) for providing student support for this project. We thank the University of Nevada, Reno Office for Clinical Research and the physicians of Renown Regional Medical Center (Drs. James Alexander, MD, Hillary Allen, MD, Holly Ashley, MD, Myron Bethel, MD, Lindsay Bridgewater, MD, Corinne Capurro, MD, Samuel Chacon, MD, Amy Condon, MD, Peter Dekay, MD, Martin Dennis, MD, Iolanda Edsall, MD, Yizhou Ernst, DO, Bruce Farringer, MD, Megan Fish, MD, Heather Fuentes, MD, Nicholas Garol, MD, Rafaela Hernandez, MD, Lester Ho, MD, Carilyn Hoffman, MD, Scott Jacobs, MD, Mary E. Kilkenny, MD, Morgan Marlow, DO, Sarah McKenzie, DO, Stacy Mellum, MD, Leah Najima, MD, Dr. Ralph Narinedhat, MD, Susan Digrazia Perry, MD, Mariko Rajamand, DO, Susan Ramos, MD, Sohini Ray, MD, Fay Roepcke, MD, Maria Sheila Sta. Maria-Torres, MD, Cynthia St Pierre, MD, Laura Thompson, MD, Vickie Tippett, MD, Arathi Veeraswamy, MD, Wagner Veronese, MD, Alison Westfall, MD, Sara Working, MD, and Jennifer Ziock-Price, MD) for their continued support of this research.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Author disclaimer
This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fbioe.2025.1632320/full#supplementary-material
SUPPLEMENTARY VIDEO S1Z-stack image of bioprinted myometrium labeled with Calcein AM (green, live cells), propidium iodide (red, dead cells), and Hoechst (blue, cell nuclei). Stacked images were captured at 20x magnification.
References
1
Adams WaldorfK. M.RubensC. E.GravettM. G. (2011). Use of nonhuman primate models to investigate mechanisms of infection-associated preterm birth. BJOG118 (2), 136–144. 10.1111/j.1471-0528.2010.02728.x
2
AguilarH. N.MitchellB. F. (2010). Physiological pathways and molecular mechanisms regulating uterine contractility. Hum. Reprod. Update16 (6), 725–744. 10.1093/humupd/dmq016
3
Alave Reyes-FurrerA.De AndradeS.BachmannD.JekerH.SteinmannM.AccartN.et al (2021). Matrigel 3D bioprinting of contractile human skeletal muscle models recapitulating exercise and pharmacological responses. Commun. Biol.4 (1), 1183. 10.1038/s42003-021-02691-0
4
AmorimP. A.d’ÁvilaM. A.AnandR.MoldenaersP.Van PuyveldeP.BloemenV. (2021). Insights on shear rheology of inks for extrusion-based 3D bioprinting. Bioprinting22, e00129. 10.1016/j.bprint.2021.e00129
5
ArrowsmithS.WrayS. (2014). Oxytocin: its mechanism of action and receptor signalling in the myometrium. J. Neuroendocrinol.26 (6), 356–369. 10.1111/jne.12154
6
BalkiM.Erik-SoussiM.KingdomJ.CarvalhoJ. C. (2014). Comparative efficacy of uterotonic agents: in vitro contractions in isolated myometrial strips of labouring and non-labouring women. Can. J. Anaesth.61 (9), 808–818. 10.1007/s12630-014-0190-1
7
BarberE. L.LundsbergL. S.BelangerK.PettkerC. M.FunaiE. F.IlluzziJ. L. (2011). Indications contributing to the increasing cesarean delivery rate. Obstet. Gynecol.118 (1), 29–38. 10.1097/AOG.0b013e31821e5f65
8
BaumbachJ.ShiS. Q.ShiL.BalducciJ.CoonrodD. V.GarfieldR. E. (2012). Inhibition of uterine contractility with various tocolytics with and without progesterone: in vitro studies. Am. J. Obstet. Gynecol.206 (3), 254.e1–254.e5. 10.1016/j.ajog.2011.12.011
9
BradleyE.BlencoweH.MollerA. B.OkwarajiY. B.SadlerF.GruendingA.et al (2025). Born too soon: global epidemiology of preterm birth and drivers for change. Reprod. Health22 (Suppl. 2), 105. 10.1186/s12978-025-02033-x
10
BuggG. J.SiddiquiF.ThorntonJ. G. (2013). Oxytocin versus no treatment or delayed treatment for slow progress in the first stage of spontaneous labour. Cochrane Database Syst. Rev.2013 (6), CD007123. 10.1002/14651858.CD007123.pub3
11
BuxtonI. L.KaiserR. A.MalmquistN. A.TichenorS. (2001). NO-induced relaxation of labouring and non-labouring human myometrium is not mediated by cyclic GMP. Br. J. Pharmacol.134 (1), 206–214. 10.1038/sj.bjp.0704226
12
ChenY.HouS. (2023). Recent progress in the effect of magnetic iron oxide nanoparticles on cells and extracellular vesicles. Cell Death Discov.9 (1), 195. 10.1038/s41420-023-01490-2
13
CherukuriR.KammalaA. K.ThomasT. J.SaylorL.RichardsonL.KimS.et al (2024). High-throughput 3D-Printed model of the feto-maternal interface for the discovery and development of preterm birth therapies. ACS Appl. Mater Interfaces16 (32), 41892–41906. 10.1021/acsami.4c08731
14
ChiossiG.CostantineM. M.BytautieneE.KechichianT.HankinsG. D.SbranaE.et al (2012). The effects of prostaglandin E1 and prostaglandin E2 on in vitro myometrial contractility and uterine structure. Am. J. Perinatol.29 (8), 615–622. 10.1055/s-0032-1311986
15
ChowL.LyeS. J. (1994). Expression of the gap junction protein connexin-43 is increased in the human myometrium toward term and with the onset of labor. Am. J. Obstet. Gynecol.170 (3), 788–795. 10.1016/s0002-9378(94)70284-5
16
CondonJ.YinS.MayhewB.WordR. A.WrightW. E.ShayJ. W.et al (2002). Telomerase immortalization of human myometrial cells. Biol. Reprod.67 (2), 506–514. 10.1095/biolreprod67.2.506
17
de ArrudaJ. S.Araujo JuniorE.Simoes MdeJ.Kulay JuniorL. (2013). Assessment of myometrial concentrations of oestrogen and progesterone receptors in the lower uterine segment of full-term pregnancies in presence or absence of labour. J. Pregnancy2013, 1–5. 10.1155/2013/213193
18
DellA. C.MarescaJ.DavisB. A.IsajiT.DardikA.GeibelJ. P. (2025). Development and deployment of a functional 3D-bioprinted blood vessel. Sci. Rep.15 (1), 11668. 10.1038/s41598-025-93276-y
19
DevostD.ZinggH. H. (2007). Novel in vitro system for functional assessment of oxytocin action. Am. J. Physiol. Endocrinol. Metab.292 (1), E1–E6. 10.1152/ajpendo.00529.2005
20
DickmanC. T. D.RussoV.ThainK.PanS.BeyerS. T.WalusK.et al (2020). Functional characterization of 3D contractile smooth muscle tissues generated using a unique microfluidic 3D bioprinting technology. FASEB J.34 (1), 1652–1664. 10.1096/fj.201901063RR
21
ElovitzM. A.MrinaliniC. (2004). Animal models of preterm birth. Trends Endocrinol. Metab.15 (10), 479–487. 10.1016/j.tem.2004.10.009
22
FangY.ReinlE. L.LiuA.ProchaskaT. D.MalikM.FrolovaA. I.et al (2024). Quantification of surface-localized and total oxytocin receptor in myometrial smooth muscle cells. Heliyon10 (4), e25761. 10.1016/j.heliyon.2024.e25761
23
FinkelS.SweetS.LockeT.SmithS.WangZ.SandiniC.et al (2023). FRESH 3D bioprinted cardiac tissue, a bioengineered platform for in vitro pharmacology. Apl. Bioeng.7 (4), 046113. 10.1063/5.0163363
24
Flores-TorresS.Peza-ChavezO.KuasneH.Munguia-LopezJ. G.Kort-MascortJ.FerriL.et al (2021). Alginate-gelatin-Matrigel hydrogels enable the development and multigenerational passaging of patient-derived 3D bioprinted cancer spheroid models. Biofabrication13 (2), 025001. 10.1088/1758-5090/abdb87
25
GallagherL. B.DolanE. B.O'SullivanJ.LeveyR.CavanaghB. L.KovarovaL.et al (2020). Pre-culture of mesenchymal stem cells within RGD-modified hyaluronic acid hydrogel improves their resilience to ischaemic conditions. Acta Biomater.107, 78–90. 10.1016/j.actbio.2020.02.043
26
GeorgiouE. X.LeiK.LaiP. F.YuliaA.HerbertB. R.CastellanosM.et al (2016). The study of progesterone action in human myometrial explants. Mol. Hum. Reprod.22 (8), 877–889. 10.1093/molehr/gaw037
27
GoldK. A.SahaB.Rajeeva PandianN. K.WaltherB. K.PalmaJ. A.JoJ.et al (2021). 3D bioprinted multicellular vascular models. Adv. Healthc. Mater10 (21), e2101141. 10.1002/adhm.202101141
28
GonzalezJ. M.FranzkeC. W.YangF.RomeroR.GirardiG. (2011). Complement activation triggers metalloproteinases release inducing cervical remodeling and preterm birth in mice. Am. J. Pathol.179 (2), 838–849. 10.1016/j.ajpath.2011.04.024
29
GribovaV.Gauthier-RouviereC.Albiges-RizoC.Auzely-VeltyR.PicartC. (2013). Effect of RGD functionalization and stiffness modulation of polyelectrolyte multilayer films on muscle cell differentiation. Acta Biomater.9 (5), 6468–6480. 10.1016/j.actbio.2012.12.015
30
HaiderS.BeristainA. G. (2023). Human organoid systems in modeling reproductive tissue development, function, and disease. Hum. Reprod.38 (8), 1449–1463. 10.1093/humrep/dead085
31
HaluskaG. J.WellsT. R.HirstJ. J.BrennerR. M.SadowskyD. W.NovyM. J. (2002). Progesterone receptor localization and isoforms in myometrium, Decidua, and fetal membranes from rhesus macaques: evidence for function progresterone withdrawal at parturtion. J. Soc. Gynecol. Investig.9 (3), 125–136. 10.1177/107155760200900303
32
HanumanS.PandeG.NuneM. (2023). Current status and challenges in uterine myometrial tissue engineering. Bioengineered14 (1), 2251847. 10.1080/21655979.2023.2251847
33
HanumanS.BH. K.PaiK. S. R.NuneM. (2024). Surface-conjugated galactose on electrospun polycaprolactone nanofibers: an innovative scaffold for uterine tissue engineering. ACS Omega9 (32), 34314–34328. 10.1021/acsomega.3c10445
34
HindsS.BianW.DennisR. G.BursacN. (2011). The role of extracellular matrix composition in structure and function of bioengineered skeletal muscle. Biomaterials32 (14), 3575–3583. 10.1016/j.biomaterials.2011.01.062
35
HockneyS.ParkerJ.TurnerJ. E.ToddX.TodrykS.GielingR. G.et al (2023). Next generation organoid engineering to replace animals in cancer drug testing. Biochem. Pharmacol.213, 115586. 10.1016/j.bcp.2023.115586
36
HowH.HuangZ. H.ZuoJ.LeiZ. M.SpinnatoJ. A.2ndRaoC. V. (1995). Myometrial estradiol and progesterone receptor changes in preterm and term pregnancies. Obstet. Gynecol.86 (6), 936–940. 10.1016/0029-7844(95)00306-C
37
HuaW.MitchellK.KariyawasamL. S.DoC.ChenJ.RaymondL.et al (2022). Three-dimensional printing in stimuli-responsive yield-stress fluid with an interactive dual microstructure. ACS Appl. Mater Interfaces14 (34), 39420–39431. 10.1021/acsami.2c12465
38
HuaW.MitchellK.RaymondL.ValentinN.CoulterR.JinY. (2023). Embedded 3D printing of PDMS-based microfluidic chips for biomedical applications. J. Manuf. Sci. Eng.145 (1), 011002. 10.1115/1.4055323
39
IlicicM.ButlerT.ZakarT.PaulJ. W. (2017). The expression of genes involved in myometrial contractility changes during ex situ culture of pregnant human uterine smooth muscle tissue. J. Smooth Muscle Res.53 (0), 73–89. 10.1540/jsmr.53.73
40
JungO.TungY. T.SimE.ChenY. C.LeeE.FerrerM.et al (2022). Development of human-derived, three-dimensional respiratory epithelial tissue constructs with perfusable microvasculature on a high-throughput microfluidics screening platform. Biofabrication14 (2), 025012. 10.1088/1758-5090/ac32a5
41
KajuluriL. P.LiY.MorganK. G. (2020). The uterine myocyte, contractile machinery and proteins of the myometrium and their relationship to the dynamic nature of myometrial function. Curr. Opin. Physiology13, 14–19. 10.1016/j.cophys.2019.09.006
42
KaneK. I. W.Lucumi MorenoE.LehrC. M.HachiS.DannertR.SanctuaryR.et al (2018). Determination of the rheological properties of matrigel for optimum seeding conditions in microfluidic cell cultures. AIP Adv.8 (12), 125332. 10.1063/1.5067382
43
KisslerK.HurtK. J. (2023). The pathophysiology of labor Dystocia: theme with variations. Reprod. Sci.30 (3), 729–742. 10.1007/s43032-022-01018-6
44
KunduS.BoutinM. E.StrongC. E.VossT.FerrerM. (2022). High throughput 3D gel-based neural organotypic model for cellular assays using fluorescence biosensors. Commun. Biol.5 (1), 1236. 10.1038/s42003-022-04177-z
45
LamontC. D.JorgensenJ. S.LamontR. F. (2016). The safety of tocolytics used for the inhibition of preterm labour. Expert Opin. Drug Saf.15 (9), 1163–1173. 10.1080/14740338.2016.1187128
46
LandisS. C.AmaraS. G.AsadullahK.AustinC. P.BlumensteinR.BradleyE. W.et al (2012). A call for transparent reporting to optimize the predictive value of preclinical research. Nature490 (7419), 187–191. 10.1038/nature11556
47
LiM.BrokawA.FurutaA. M.ColerB.Obregon-PerkoV.ChahroudiA.et al (2021a). Non-human primate models to investigate mechanisms of infection-associated fetal and pediatric injury, teratogenesis and stillbirth. Front. Genet.12, 680342. 10.3389/fgene.2021.680342
48
LiW. J.LuJ. W.ZhangC. Y.WangW. S.YingH.MyattL.et al (2021b). PGE2 vs PGF2α in human parturition. Placenta104, 208–219. 10.1016/j.placenta.2020.12.012
49
LiS.DanX.ChenH.LiT.LiuB.JuY.et al (2024). Developing fibrin-based biomaterials/scaffolds in tissue engineering. Bioact. Mater40, 597–623. 10.1016/j.bioactmat.2024.08.006
50
LiangZ.LiuC.LiL.XuP.LuoG.DingM.et al (2016). Double-network hydrogel with tunable mechanical performance and biocompatibility for the fabrication of stem cells-encapsulated fibers and 3D assemble. Sci. Rep.6 (1), 33462. 10.1038/srep33462
51
LiuW.HeinrichM. A.ZhouY.AkpekA.HuN.LiuX.et al (2017). Extrusion bioprinting of shear-thinning gelatin methacryloyl bioinks. Adv. Healthc. Mater6 (12), 1601451. 10.1002/adhm.201601451
52
LiuX.MichaelS.BhartiK.FerrerM.SongM. J. (2020). A biofabricated vascularized skin model of atopic dermatitis for preclinical studies. Biofabrication12 (3), 035002. 10.1088/1758-5090/ab76a1
53
Lopez BernalA.Canete SolerR.TurnbullA. C. (1989). Are leukotrienes involved in human uterine contractility?Br. J. Obstet. Gynaecol.96 (5), 568–573. 10.1111/j.1471-0528.1989.tb03258.x
54
LopezT. E.ZhangH.BouysseE.NeiersF.YeX. Y.GarridoC.et al (2024). A pivotal role for the IL-1β and the inflammasome in preterm labor. Sci. Rep.14 (1), 4234. 10.1038/s41598-024-54507-w
55
MalikM.RohM.EnglandS. K. (2021). Uterine contractions in rodent models and humans. Acta Physiol. (Oxf)231 (4), e13607. 10.1111/apha.13607
56
MaxeyA. P.McCainM. L. (2021). Tools, techniques, and future opportunities for characterizing the mechanobiology of uterine myometrium. Exp. Biol. Med. (Maywood)246 (9), 1025–1035. 10.1177/1535370221989259
57
MesianoS.ChanE. C.FitterJ. T.KwekK.YeoG.SmithR. (2002). Progesterone withdrawal and estrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium. J. Clin. Endocrinol. Metab.87 (6), 2924–2930. 10.1210/jcem.87.6.8609
58
MinS.KimS.SimW. S.ChoiY. S.JooH.ParkJ. H.et al (2024). Versatile human cardiac tissues engineered with perfusable heart extracellular microenvironment for biomedical applications. Nat. Commun.15 (1), 2564. 10.1038/s41467-024-46928-y
59
MitchellB. F.TaggartM. J. (2009). Are animal models relevant to key aspects of human parturition?Am. J. Physiol. Regul. Integr. Comp. Physiol.297 (3), R525–R545. 10.1152/ajpregu.00153.2009
60
MoysidouC. M.BarberioC.OwensR. M. (2020). Advances in engineering human tissue models. Front. Bioeng. Biotechnol.8, 620962. 10.3389/fbioe.2020.620962
61
MyattL.LyeS. J. (2004). Expression, localization and function of prostaglandin receptors in myometrium. Prostagl. Leukot. Essent. Fat. Acids70 (2), 137–148. 10.1016/j.plefa.2003.04.004
62
NielsenB. W.BonneyE. A.PearceB. D.DonahueL. R.SarkarI. N.Preterm Birth InternationalC. (2016). A cross-species analysis of animal models for the investigation of preterm birth mechanisms. Reprod. Sci.23 (4), 482–491. 10.1177/1933719115604729
63
OsagieJ. O.SyedaS. S.Turner-BrannenE.GuimondM.ParrenasL.HaroonA.et al (2022). Development of a 3D bioprinted airway smooth muscle model for manipulating structure and measuring contraction. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
64
OstermanM.HamiltonB.MartinJ. A.DriscollA. K.ValenzuelaC. P. (2021). Births: final data for 2020. Natl. Vital Stat. Rep.70 (17), 1–50. 10.15620/cdc:112078
65
ParkG.RimY. A.SohnY.NamY.JuJ. H. (2024). Replacing animal testing with stem cell-organoids: advantages and limitations. Stem Cell Rev. Rep.20 (6), 1375–1386. 10.1007/s12015-024-10723-5
66
PehlivanogluB.BayrakS.DoganM. (2013). A close look at the contraction and relaxation of the myometrium; the role of calcium. J. Turk Ger. Gynecol. Assoc.14 (4), 230–234. 10.5152/jtgga.2013.67763
67
QuaasL.GoppingerA.ZahradnikH. P. (1987). The effect of acetylsalicylic acid and indomethacin on the catecholamine- and oxytocin-induced cotractility and prostaglandin (6-keto-PGF1a, PGF2a)-production of human pregnant myometrial strips. Prostaglandins34 (2), 257–269. 10.1016/0090-6980(87)90248-6
68
RezapourM.BackstromT.UlmstenU. (1996). Myometrial steroid concentration and oxytocin receptor density in parturient women at term. Steroids61 (6), 338–344. 10.1016/0039-128x(96)00035-9
69
RicciottiE.FitzGeraldG. A. (2011). Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol.31 (5), 986–1000. 10.1161/ATVBAHA.110.207449
70
Sanchez-RamosL.LevineL. D.SciscioneA. C.MozurkewichE. L.RamseyP. S.AdairC. D.et al (2024). Methods for the induction of labor: efficacy and safety. Am. J. Obstet. Gynecol.230 (3S), S669–S695. 10.1016/j.ajog.2023.02.009
71
SmithA. S.LuttrellS. M.DupontJ. B.GrayK.LihD.FlemingJ. W.et al (2022). High-throughput, real-time monitoring of engineered skeletal muscle function using magnetic sensing. J. Tissue Eng.13, 20417314221122127. 10.1177/20417314221122127
72
SongM. J.QuinnR.NguyenE.HamptonC.SharmaR.ParkT. S.et al (2023). Bioprinted 3D outer retina barrier uncovers RPE-dependent choroidal phenotype in advanced macular degeneration. Nat. Methods20 (1), 149–161. 10.1038/s41592-022-01701-1
73
SouzaG. R.TsengH.GageJ. A.ManiA.DesaiP.LeonardF.et al (2017). Magnetically bioprinted human myometrial 3D cell rings as A model for uterine contractility. Int. J. Mol. Sci.18 (4), 683. 10.3390/ijms18040683
74
SunJ.ChongJ.ZhangJ.GeL. (2023). Preterm pigs for preterm birth research: reasonably feasible. Front. Physiol.14, 1189422. 10.3389/fphys.2023.1189422
75
ThorrezL.DiSanoK.ShanskyJ.VandenburghH. (2018). Engineering of human skeletal muscle with an autologous deposited extracellular matrix. Front. Physiol.9, 1076. 10.3389/fphys.2018.01076
76
TsuiJ. H.ZepedaB.SteltzerS. S.HoJ. J.PriestJ.HoeyT. (2022). Abstract P2121: modeling genetic dilated cardiomyopathies with engineered heart tissues from patient-derived and isogenic mutant induced pluripotent stem cells. Circulation Res.131 (Suppl. l_1), AP2121. 10.1161/res.131.suppl_1.P2121
77
TungY. T.ChenY. C.DerrK.WilsonK.SongM. J.FerrerM. (2024). A 3D bioprinted human neurovascular unit model of glioblastoma tumor growth. Adv. Healthc. Mater13 (15), e2302831. 10.1002/adhm.202302831
78
UlrichC. C.ArinzeV.WandscheerC. B.Copley SalemC.NabatiC.Etezadi-AmoliN.et al (2019). Matrix metalloproteinases 2 and 9 are elevated in human preterm laboring uterine myometrium and exacerbate uterine contractility. Biol. Reprod.100 (6), 1597–1604. 10.1093/biolre/ioz054
79
UlrichC. C.ParkerL. L.LambertJ. A.BaldwinL.BuxtonI. L. O.Etezadi-AmoliN.et al (2025). Matrix metallopeptidase 9 promotes contraction in human uterine myometrium. Reprod. Sci.32 (2), 444–454. 10.1007/s43032-024-01778-3
80
Uvnas-MobergK. (2024). The physiology and pharmacology of oxytocin in labor and in the peripartum period. Am. J. Obstet. Gynecol.230 (3S), S740–S758. 10.1016/j.ajog.2023.04.011
81
VigneaudV. d.ResslerC.SwanC. J. M.RobertsC. W.KatsoyannisP. G.GordonS. (2002). The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J. Am. Chem. Soc.75 (19), 4879–4880. 10.1021/ja01115a553
82
WangD.ZengJ.ZhuH.LiuS.JiaL.LiuW.et al (2024). Extrusion bioprinting of elastin‐containing bioactive double‐network tough hydrogels for complex elastic tissue regeneration. Aggregate5 (3), e477. 10.1002/agt2.477
83
WheelerE. E.LeachJ. K. (2025). Tissue-engineered three-dimensional platforms for disease modeling and therapeutic development. Tissue Eng. Part B Rev.31 (4), 390–405. 10.1089/ten.TEB.2024.0212
84
WorkmanM. J.MaheM. M.TrisnoS.PolingH. M.WatsonC. L.SundaramN.et al (2017). Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system. Nat. Med.23 (1), 49–59. 10.1038/nm.4233
85
WrayS.ArrowsmithS. (2021). Uterine excitability and ion channels and their changes with gestation and hormonal environment. Annu. Rev. Physiol.83 (1545-1585 (Electronic)), 331–357. 10.1146/annurev-physiol-032420-035509
86
ZhuH.KimY. D.De KeeD. (2005). Non-newtonian fluids with a yield stress. J. Newt. Fluid Mech.129 (3), 177–181. 10.1016/j.jnnfm.2005.06.001
Summary
Keywords
uterus, labor, myometrium, pregnancy, bioprinting, tissue model
Citation
Ulrich C, Siddiqui K, Baldwin LK, Hua W, Kuklok JK, Okaikoi JJ, Parker LL, Petereit J, Quilici DR, Silva GM, Sivakoses A, Wong-Fortunato JS, Woolsey RJ, West A, Jin Y and Burkin H (2025) A bioprinted model of pregnant human uterine myometrium. Front. Bioeng. Biotechnol. 13:1632320. doi: 10.3389/fbioe.2025.1632320
Received
21 May 2025
Accepted
17 October 2025
Published
30 October 2025
Volume
13 - 2025
Edited by
Ana Claudia Oliveira Carreira, Federal University of ABC, Brazil
Reviewed by
Renea Sturm, UCLA Mattel Children’s Hospital, United States
Manasa, Manipal Institute of Regenerative Medicine, India
Updates
Copyright
© 2025 Ulrich, Siddiqui, Baldwin, Hua, Kuklok, Okaikoi, Parker, Petereit, Quilici, Silva, Sivakoses, Wong-Fortunato, Woolsey, West, Jin and Burkin.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Heather Burkin., hburkin@med.unr.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.